One size fits all: The story of SGLT2 inhibitors in heart failure

Subodh Verma; Nitish K Dhingra; Deepak L Bhatt; Nikolaus Marx; Francesco Cosentino

doi:10.1016/j.medj.2022.10.001

One size fits all: The story of SGLT2 inhibitors in heart failure

Med. 2022 Nov 11;3(11):735-739. doi: 10.1016/j.medj.2022.10.001. Epub 2022 Oct 28.

Authors

Subodh Verma¹, Nitish K Dhingra², Deepak L Bhatt³, Nikolaus Marx⁴, Francesco Cosentino⁵

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, ON, Canada. Electronic address: subodh.verma@unityhealth.to.
² Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
³ Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
⁴ Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany.
⁵ Cardiology Unit, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden.

PMID: 36309012
DOI: 10.1016/j.medj.2022.10.001

Abstract

EMPEROR-Preserved and DELIVER have ushered in a new era for the treatment of heart failure with a preserved ejection fraction (HFpEF). In this commentary, we compare the characteristics and findings of these two trials and assess their implications for the broader management of the heart failure syndrome.

MeSH terms

Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Stroke Volume

Substances

Sodium-Glucose Transporter 2 Inhibitors